[5-fluoro-4-(7-fluoro-3-isopropyl-2-methyl-3H-benzoimidazol-5-yl)-pyrimidin-2-yl]-[5-(4-isopropyl-piperazin-1-ylmethyl)-pyridin-2-yl]-amine | 1231929-98-8

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 苯并咪唑类
• 英文名称: [5-fluoro-4-(7-fluoro-3-isopropyl-2-methyl-3H-benzoimidazol-5-yl)-pyrimidin-2-yl]-[5-(4-isopropyl-piperazin-1-ylmethyl)-pyridin-2-yl]-amine
• 英文别名: 5-fluoro-4-(7-fluoro-2-methyl-3-propan-2-ylbenzimidazol-5-yl)-N-[5-[(4-propan-2-ylpiperazin-1-yl)methyl]pyridin-2-yl]pyrimidin-2-amine
• CAS: 1231929-98-8
• 化学式: C₂₈H₃₄F₂N₈
• 分子量: 520.628
• InChiKey: OQHSJWFTOYXFRG-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  4.3
• 重原子数：
  38
• 可旋转键数：
  7
• 环数：
  5.0
• sp3杂化的碳原子比例：
  0.43
• 拓扑面积：
  75
• 氢给体数：
  1
• 氢受体数：
  9

反应信息

• 作为产物：
  描述：

  5-氟-4-(4-氟-1-异丙基-2-甲基-1H-苯并[D]咪唑-6-基)-N-[5-(1-哌嗪基甲基)-2-吡啶基]嘧啶-2-胺 、 丙酮 在 三乙酰氧基硼氢化钠 、 溶剂黄146 、 氨 作用下， 以 1,2-二氯乙烷 、 甲醇 为溶剂， 反应 1.0h， 生成 [5-fluoro-4-(7-fluoro-3-isopropyl-2-methyl-3H-benzoimidazol-5-yl)-pyrimidin-2-yl]-[5-(4-isopropyl-piperazin-1-ylmethyl)-pyridin-2-yl]-amine
  参考文献：
  名称：

  PROTEIN KINASE INHIBITORS

  摘要：

  本发明提供了化合物的结构式(I)：或其药用可接受的盐，可用于治疗细胞增殖性疾病。

  公开号：

  US20100160340A1

文献信息

• NOVEL SELECTIVE CDK4/6 INHIBITOR AND PREPARATION THEREOF
  申请人：Wuxi Shuangliang Biotechnology Co., Ltd.

  公开号：US20200339572A1

  公开（公告）日：2020-10-29

  The present disclosure discloses a compound as represented by formula (I) or a pharmaceutically acceptable salt, a solvate or an isomer thereof, a pharmaceutical composition and a pharmaceutical preparation comprising the same, and the application thereof in the field of medicine. As a selective inhibitor of cyclin-dependent kinase 4/6 (CDK4/6), the compound of the present disclosure may be used for treating or preventing a disease at least partially modulated by CDK4/6, such as breast cancer and colon cancer. PBM-L-PDM   (I)

  本公开揭示了一种由化学式（I）表示的化合物或其药学上可接受的盐、溶剂合物或异构体，以及包括该化合物的药物组合物和药物制剂，以及其在医学领域中的应用。作为cyclin-dependent kinase 4/6（CDK4/6）的选择性抑制剂，本公开的化合物可用于治疗或预防至少部分由CDK4/6调节的疾病，如乳腺癌和结肠癌。PBM-L-PDM  （I）
• [EN] PROTEIN KINASE INHIBITORS<br/>[FR] INHIBITEURS DE PROTÉINE KINASES
  申请人：LILLY CO ELI

  公开号：WO2010075074A1

  公开（公告）日：2010-07-01

  The present invention provides a compound of formula (I) or a pharmaceutically acceptable salt thereof which is useful in the treatment of cell proliferative diseases.

  本发明提供了式（I）的化合物或其药学上可接受的盐，其在治疗细胞增殖性疾病方面是有用的。
• Protein kinase inhibitors
  申请人：Eli Lilly and Company

  公开号：US07855211B2

  公开（公告）日：2010-12-21

  The present invention provides a compound of formula (I): or a pharmaceutically acceptable salt thereof which is useful in the treatment of cell proliferative diseases.

  本发明提供了式（I）的化合物：或其药学上可接受的盐，其在细胞增殖性疾病的治疗中有用。
• Therapeutic Combinations of a BTK Inhibitor, a PI3K Inhibitor, a JAK-2 Inhibitor, and/or a CDK 4/6 Inhibitor
  申请人：Acerta Pharma B.V.

  公开号：US20170224819A1

  公开（公告）日：2017-08-10

  Therapeutic combinations of a phosphoinositide 3-kinase (PI3K) inhibitor, including PI3K inhibitors selective for the γ- and δ-isoforms and selective for both γ- and δ-isoforms (PI3K-γ,δ, PI3K-γ, and PI3K-δ, a Janus kinase-2 (JAK-2) inhibitor, a cyclin-dependent kinase-4/6 (CDK4/6) inhibitor, and/or a Bruton's tyrosine kinase (BTK) inhibitor are described. In certain embodiments, the invention includes therapeutic combinations of a cyclin-dependent kinase-4/6 (CDK4/6) inhibitor and a BTK inhibitor, a PI3K-δ inhibitor and a BTK inhibitor, a JAK-2 and a BTK inhibitor, and a JAK-2, PI3K-δ, and BTK inhibitor.
• PHOTOSWITCHABLE PROTACS AND SYNTHESIS AND USES THEREOF
  申请人：New York University

  公开号：US20220143183A1

  公开（公告）日：2022-05-12

  Provided are compounds, which may be referred to as PHOTACs (photoswitchable proteolysis targeting chimeras), and compositions, kits, and methods of making and using PHOTACs. PHOTACs have one or more E3 ligase ligand(s), one or more photoswitchable group(s), optionally, one or more linker(s), and one or more ligand(s) for a target protein. PHOTACs may be suitable for use in methods to treat diseases, such as, for example, cancer. PHOTACs may also be suitable for use in methods to induce selective degradation of a target protein.